Intravitreal Bevacizumab for Inflammatory Neovascular Membranes

Phase 3

Withdrawn

• Conditions: Multifocal Choroiditis; Serpiginous Choroiditis; Vogt Koyanagi Harada Disease

• Registration Number: NCT00407121
• Lead Sponsor: Asociación para Evitar la Ceguera en México

Brief Summary

Intravitreal injection of Bevacizumab in patients with Neovascular Membranes secondary to intraocular inflammation. We injected a single injection of Bevacizumab (2.5 mg/0.1 ml) and evaluate visual acuity , Fluorescein angiogram and retinal thickness by Optical Coherence Tomography (OCT) in 4 patients with Vogt Koyanagi Harada disease, 1 patient with Serpiginous Choroidopathy and 1 patient with Multifocal Choroiditis.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-12
• Primary Completion: 2006-12
• Study Completion: 2006-12
• Study First Submitted: 2006-12-01
• Study First Submitted QC: 2006-12-01
• Study First Posted: 2006-12-04
• Status Verified: 2024-05
• Last Update Submitted: 2024-05-29
• Last Update Posted: 2024-05-30

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Clinical Diagnose
• Patient Consent
• Chronic stage of inflammation

Exclusion Criteria

• only eye
• age lower than 30 yo.
• Systemic condition

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Best corrected visual acuity
Retinal thickness by OCT
Leakage in Fluorescein angiogram

Trial Locations

Locations (1)

Asociacion para Evitar la Ceguera en Mexico; 🇲🇽 Mexico, Distrito Federal, Mexico